7 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-boundNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 32026-07-21NCT07716228
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab DeruxtecanNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 32026-07-21NCT07716189
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus CyclophosphamideNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 32026-07-21NCT07716176
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus CyclophosphamideNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 22026-04-17NCT07537699
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab DeruxtecanNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 22026-04-17NCT07537673
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus PaclitaxelNausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, DigestiveRecruitingPhase 22026-04-17NCT07537660
Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System (GIANT Study)Aneurysm, Aneurysm, Aortic Arch, aortic aneurysm, aortic disorder, cardiovascular disorder, thoracic aortic aneurysm, vascular disorderActive, not recruitingNot applicable2024-04-30NCT04765592